Drug Research
At $3.5M Hemgenix From CSL- uniQure The Costliest Medicine
There is a new medicine that has surpassed Bluebird Bio as the costliest in the world.
Hemgenix, a haemophilia B gene therapy developed by CSL Behring...
Drug Research
EMA Develops A Quality Control Group To Aid Drug Development
To support innovative approaches for the development, manufacture, and quality control (QC) of medicines, along with new technologies, digitalization, novel materials, and novel devices for...
Drug Research
RVAC Medicines and A*STAR to Build Capabilities for mRNA Production in Singapore
RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company incubated by CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, and the Agency for...
Drug Research
Merck Invests € 290 Million in U.S. Drug Safety Testing Capacity
Merck, a leading science and technology company, invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA. This will significantly...
Drug Research
Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems
The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched to ensure the growing threats and impacts of antimicrobial resistance are addressed globally.
The Food and Agriculture Organization...
Drug Research
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform...
Drug Research
Australia Offers A Nasal Vaccine To Guard Against COVID-19
Researchers from Australia's Centenary Institute and the University of Sydney have created a novel nasal vaccination system that promotes strong lung resistance and tolerance against...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.